Congenica Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Congenica's estimated annual revenue is currently $14.6M per year.(i)
  • Congenica's estimated revenue per employee is $155,000

Employee Data

  • Congenica has 94 Employees.(i)
  • Congenica grew their employee count by -19% last year.

Congenica's People

NameTitleEmail/Phone
1
Product OwnerReveal Email/Phone
2
Chief Technology OfficerReveal Email/Phone
3
Interim CFOReveal Email/Phone
4
Chief Organisation Development & Talent OfficerReveal Email/Phone
5
Chief Product OfficerReveal Email/Phone
6
Chief Scientific OfficerReveal Email/Phone
7
SVP, Genomic Insights and SolutionsReveal Email/Phone
8
Head ProductReveal Email/Phone
9
Head Customer SupportReveal Email/Phone
10
Head HRReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.5M29-12%N/AN/A
#2
$15.7M1015%N/AN/A
#3
$87.9M40525%$292MN/A
#4
$2.6M47016%$631.7MN/A
#5
$14.9M96-8%$81MN/A
#6
$44.8M2310%$132.9MN/A
#7
$7.6M49-37%N/AN/A
#8
$17.4M11212%N/AN/A
#9
$334.6M134911%£994.6MN/A
#10
$830.2M53568%N/AN/A
Add Company

What Is Congenica?

Congenica is a digital health company with the world’s leading clinical decision support platform for accelerated genomic data interpretation. \n\nOur software enables genomic medicine by integrating genetic data into healthcare, empowering clinicians to provide life-changing answers that transform the lives of individuals, patients and their families.\n \nGenetic diseases are technically difficult to diagnose, and patients often spend years waiting for a diagnosis. We convert genomic data into actionable information, expediting the process through more efficient and accurate analysis. This supports healthcare professionals in providing patients with robust diagnoses and precise, personalised care. \n \nBorn out of pioneering research from the Wellcome Sanger Institute and the NHS, we are headquartered in Cambridge, UK, with a global footprint across the US and China. Our platform is validated by the pivotal Genomics England 100,000 Genomes Project and we are the exclusive clinical interpretation partner to the NHS Genomic Medicine Service.

keywords:N/A

N/A

Total Funding

94

Number of Employees

$14.6M

Revenue (est)

-19%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Congenica News

2022-04-06 - Comparative Genomic Hybridization (CGH) Software Market ...

... (CGH) Software Market 2022 Global Future Forecasts – Agilent Technologies, QIAGEN Digital Insights, Fabric Genomics, Congenica.

2022-03-22 - Congenica to Provide Tertiary Analysis for Whole Genome ...

Congenica is a digital health company enabling the rapid analysis and interpretation of genomic data, empowering researchers and clinicians to...

2021-01-14 - Congenica launches Patient Advocacy and Engagement Advisory Board

Congenica launches Patient Advocacy and Engagement Advisory Board 14-01-2021 Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, announces the launch of a Patient Advocacy and Engagement Advisory Board. Working with th ...

2021-01-14 - Congenica launches Patient Advocacy and Engagement Advisory Board

Congenica launches Patient Advocacy and Engagement Advisory Board 14-01-2021 Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, announces the launch of a Patient Advocacy and Engagement Advisory Board. Working with th ...

2020-11-11 - Malaysia’s Xeraya Capital invests in Congenica’s $50m Series C funding round

Malaysia-based private equity firm Xeraya Capital announced on Wednesday its participation in a globally syndicated $50 million Series C investment in Congenica, a UK-headquartered digital health company that claims to provide rapid and accurate analysis of complex genomic data. The round was c ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$23.1M9431%N/A
#2
$14.6M9427%N/A
#3
$14.7M95-11%N/A
#4
$15M9671%N/A
#5
$27.8M961%N/A